Chemistry:Imeglimin

From HandWiki

Imeglimin (EMD- 387008,PXL- 008,RVT-1501, brand name Twymeeg) is an oral anti-diabetic medication.[1][2] It was approved for use in Japan in June 2021.[3]

It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It is the first approved drug of this class of anti-diabetic medication.

References

  1. ↑ "Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes". Drugs in R&D 15 (3): 227–32. September 2015. doi:10.1007/s40268-015-0099-3. PMID 26254210. 
  2. ↑ "Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial". Diabetes Care 44 (4): 952–959. April 2021. doi:10.2337/dc20-0763. PMID 33574125. 
  3. ↑ Poxel SA (June 23, 2021). "Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan" (Press release).



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Imeglimin&oldid=4032848"